Evidence map›Paper›PMID 31564913›Full record

ArticleOncoTargets and therapy2019

MicroRNA-675 directly targets MAPK1 to suppress the oncogenicity of papillary thyroid cancer and is sponged by long non-coding RNA RMRP.

Junyi Wang, Tiantian Xiao, Ming Zhao

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in OncoTargets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. NLRP3: Role in ischemia/reperfusion injuries.Frontiers in immunology · 2022
    Review
  6. Article
  7. Article
  8. ALKBH5-mediated m6A demethylation of lncRNA RMRP plays an oncogenic role in lung adenocarcinoma.Mammalian genome : official journal of the International Mammalian Genome Society · 2021
    Article
  9. Article
  10. LncRNAInternational journal of molecular sciences · 2021
    Article
  11. Article
  12. Article
  13. Long Non-coding RNA RMRP in the Pathogenesis of Human Disorders.Frontiers in cell and developmental biology · 2021
    Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Junyi Wang *Department of Endocrinology, Geriatric Research Center, JinLing Hospital, Nanjing, Medical School of Nanjing University, Jiangsu 210002, People's Republic of China.
Tiantian Xiao *Department of Endocrinology, Geriatric Research Center, JinLing Hospital, Nanjing, Medical School of Nanjing University, Jiangsu 210002, People's Republic of China.
Ming ZhaoDepartment of Endocrinology, Geriatric Research Center, JinLing Hospital, Nanjing, Medical School of Nanjing University, Jiangsu 210002, People's Republic of China.
Jinling Institute of Technology · CNNanjing University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMicroRNA-675-5p (miR-675-5p) is dysregulated in multiple human cancers, but its involvement in papillary thyroid cancer (PTC) remains to be investigated. This study aimed to examine the expression pattern of miR-675 in PTC, determine the effects of miR-675 on regulating the progression of PTC, and to explore the underlying molecular mechanisms.

methodsThe expression profile of miR-675 in PTC tissues and cell lines was determined using RT-qPCR. CCK-8, transwell migration and invasion assays, and xenograft tumors in nude mice were employed to analyze proliferation, in vitro migration and invasion, and in vivo tumor growth of PTC cells, respectively. The putative target of miR-675 was predicted using bioinformatic algorithms and was confirmed using luciferase reporter assays, RT-qPCR, and Western blotting.

resultsmiR-675 expression was decreased in PTC tissues and cell lines. A low level of miR-675 expression was significantly correlated with lymphatic metastasis and TNM stage in PTC patients. Ectopic miR-675 expression suppressed PTC cell proliferation, migration, and invasion in vitro and hindered tumor growth in vivo. Mitogen-activated protein kinase 1 (MAPK1) was found to be the direct target gene of miR-675 in PTC cells. MAPK1 reintroduction negated the tumor-suppressing effect of miR-675 overexpression in PTC cells. Furthermore, the lncRNA mitochondrial RNA processing endoribonuclease (RMRP) functioned as a ceRNA of miR-675 in PTC cells. Silencing RMRP expression inhibited the growth and metastasis of PTC cells by sponging miR-675 and regulating MAPK1.

conclusionThese findings revealed that miR-675 directly targets MAPK1 and is sponged by lncRNA RMRP to inhibit the oncogenicity of PTC, suggesting the RMRP-miR-675-MAPK1 pathway is an effective target for the treatment of PTC patients.

Indexed as

component of mitochondrial RNA processing endoribonucleasemicroRNA-675mitogen-activated protein kinase 1papillary thyroid cancer

Identifiers

PMID31564913
PMCPMC6735657
OpenAlexW2972302839

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.